|Print Page Close Window|
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).
09/13/17AVEO Oncology Announces Receipt of Payments from EUSA Pharma and CANbridgeRead More
09/05/17AVEO Oncology to Present at Upcoming ConferencesRead More
08/28/17AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell CarcinomaRead More
09/27/17 4:00 p.m. ET AVEO Oncology at the Cantor Fitzgerald 2017 Global Healthcare Conference
Corporate PresentationAVEO Oncology Corporate Presentation